Cargando…
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521968/ https://www.ncbi.nlm.nih.gov/pubmed/28615237 http://dx.doi.org/10.2337/dc17-er08d |
| _version_ | 1783252075262509056 |
|---|---|
| author | Abdul-Ghani, Muhammad Migahid, Osama Megahed, Ayman Adams, John Triplitt, Curtis DeFronzo, Ralph A. Zirie, Mahmoud Jayyousi, Amin |
| author_facet | Abdul-Ghani, Muhammad Migahid, Osama Megahed, Ayman Adams, John Triplitt, Curtis DeFronzo, Ralph A. Zirie, Mahmoud Jayyousi, Amin |
| author_sort | Abdul-Ghani, Muhammad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5521968 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55219682018-03-29 Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 Abdul-Ghani, Muhammad Migahid, Osama Megahed, Ayman Adams, John Triplitt, Curtis DeFronzo, Ralph A. Zirie, Mahmoud Jayyousi, Amin Diabetes Care Errata American Diabetes Association 2017-08 2017-06-14 /pmc/articles/PMC5521968/ /pubmed/28615237 http://dx.doi.org/10.2337/dc17-er08d Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata Abdul-Ghani, Muhammad Migahid, Osama Megahed, Ayman Adams, John Triplitt, Curtis DeFronzo, Ralph A. Zirie, Mahmoud Jayyousi, Amin Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title | Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title_full | Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title_fullStr | Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title_full_unstemmed | Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title_short | Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331 |
| title_sort | erratum. combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin: the qatar study. diabetes care 2017;40:325–331 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521968/ https://www.ncbi.nlm.nih.gov/pubmed/28615237 http://dx.doi.org/10.2337/dc17-er08d |
| work_keys_str_mv | AT abdulghanimuhammad erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT migahidosama erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT megahedayman erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT adamsjohn erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT triplittcurtis erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT defronzoralpha erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT ziriemahmoud erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 AT jayyousiamin erratumcombinationtherapywithexenatidepluspioglitazoneversusbasalbolusinsulininpatientswithpoorlycontrolledtype2diabetesonsulfonylureaplusmetformintheqatarstudydiabetescare201740325331 |